AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD) – UC and ...
Electrocaloric effects are large in a limited set of materials that display hysteretic first-order phase transitions. Here epitaxial SrTiO 3 thin films are strain engineered to achieve anhysteretic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results